Are COVID-19 Vaccine Trials in Violation of Ethical Norms by Not Disclosing ADE Risks?

Are COVID-19 Vaccine Trials in Violation of Ethical Norms by Not Disclosing ADE Risks

An associate professor from NYU Langone Health’s Department of Biochemistry and Molecular Pharmacology along with a Professor and Chair, Division of Comparative Pathology with the Tulane School of Medicine, produced a peer-reviewed, published call for improving the informed consent process during the COVID-19 pandemic, and now.  Why? Because according to Timothy J. Cardozo, MD, PhD, (NYU Langone) and Ronald S. Veazey, DVM, PhD, a specific and significant COVID-19 vaccine risk of antibody-dependent enhancement (ADE) must be disclosed to research subjects participating in the clinical trials evaluating the investigational vaccine products.The two medical researchers remind their peers in the research business that patient comprehension, that is the obligation of the research physician and staff to communicate any risks to the patient in a way so that they can comprehend such risks associated with a particular investigational treatment, is actually foundational to the research imperative.  Driven by the Declaration of Helsinki, the patient’s understanding of what is happening isn’t a luxury of research, it’s a necessity. Hence the Cardozo and Veazey study sought to better understand ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee